# Clinical Cases: RNA Viruses

## Case 1: Influenza Complicated by Bacterial Superinfection

### Presentation
A 68-year-old woman with COPD and diabetes presents with 5 days of fever, myalgias, and dry cough that initially improved but then worsened over the past 2 days. She developed new productive cough with rust-colored sputum, shaking chills, and worsening dyspnea. She did not receive the influenza vaccine this season. Vital signs: temperature 39.8°C, heart rate 108 bpm, respiratory rate 28/min, oxygen saturation 89% on room air. Chest radiograph shows bilateral patchy infiltrates with a new right lower lobe consolidation. Nasal swab PCR is positive for influenza A.

### Clinical Image
![Chest X-ray showing post-influenza pneumonia](image_01.png)
*Chest radiograph demonstrating bilateral patchy infiltrates with right lower lobe consolidation, consistent with influenza pneumonia complicated by bacterial superinfection.*

**Image Source**: Lecture image - influenza complications

### Questions

1. **What complication has developed, and what organisms are most commonly responsible?**

2. **Why are patients with influenza at increased risk for bacterial superinfection?**

3. **What is the role of antiviral therapy at this stage of illness?**

4. **How could this complication have been prevented?**

### Answers

1. **Complication and organisms**: This patient has developed **secondary bacterial pneumonia** complicating influenza infection. The biphasic illness pattern (initial improvement followed by worsening) is classic for bacterial superinfection. The most common organisms are:
   - **Streptococcus pneumoniae** (most common)
   - **Staphylococcus aureus** (including MRSA - particularly concerning)
   - **Haemophilus influenzae**
   - **Streptococcus pyogenes**

   The rust-colored sputum is suggestive of pneumococcal infection.

2. **Increased risk for bacterial superinfection**: Influenza increases susceptibility to bacterial pneumonia through multiple mechanisms:
   - **Epithelial damage**: Viral replication destroys respiratory epithelium and disrupts mucociliary clearance
   - **Upregulation of bacterial adhesion receptors** on damaged epithelium
   - **Impaired immune function**: Influenza suppresses macrophage and neutrophil function
   - **Neuraminidase**: Viral neuraminidase exposes bacterial binding sites by cleaving sialic acid residues
   - **Inflammatory response**: Dysregulated inflammation may contribute to tissue damage

3. **Role of antiviral therapy**: Although typically most effective when started within 48 hours of symptom onset, **antiviral therapy (oseltamivir)** may still provide benefit in:
   - Hospitalized patients (regardless of timing)
   - Patients with severe or progressive illness
   - Patients at high risk for complications

   This patient should receive **both** oseltamivir AND empiric antibiotics covering typical bacterial pathogens (including S. aureus given severity). Antivirals can reduce viral shedding, potentially limiting further epithelial damage and improving outcomes even late in the illness course.

4. **Prevention**:
   - **Annual influenza vaccination**: Most important preventive measure, particularly for high-risk groups (elderly, chronic diseases)
   - **Pneumococcal vaccination**: This patient should also receive pneumococcal vaccines (PCV20 or PCV15 + PPSV23)
   - **Early antiviral therapy**: If influenza develops despite vaccination, early oseltamivir can reduce severity and complications
   - **Hand hygiene and respiratory precautions** during influenza season

---

## Case 2: Rabies Exposure

### Presentation
A 35-year-old hiker presents to the emergency department after being bitten on the hand by a bat while camping in a cave. The bite occurred 6 hours ago when he tried to remove a bat that had landed on his backpack. He has a small puncture wound on his right index finger with minimal bleeding. He is otherwise healthy with no symptoms. His tetanus vaccination is current. The bat was not captured.

### Clinical Image
![Post-exposure prophylaxis for rabies](image_02.png)
*Diagram illustrating the components of rabies post-exposure prophylaxis: wound care, human rabies immune globulin (HRIG) infiltration at the wound site, and rabies vaccine series.*

**Image Source**: Lecture image - rabies prevention

### Questions

1. **Why is this considered a high-risk exposure requiring post-exposure prophylaxis?**

2. **What are the components of rabies post-exposure prophylaxis (PEP)?**

3. **What is the rationale for the different components of PEP?**

4. **What is the prognosis if rabies infection develops?**

### Answers

1. **High-risk exposure rationale**: This is a high-risk rabies exposure for several critical reasons:
   - **Bats are major rabies reservoirs** in the United States (causing most human rabies cases)
   - **The bat was not captured** for testing, so rabies status is unknown
   - Bat bites can be **very small or unrecognized**, and any direct contact with a bat (even without obvious bite) may warrant PEP
   - **Bat rabies variants** are particularly adapted for transmission to humans
   - Rabies is **nearly 100% fatal** once clinical symptoms develop

   For bat exposures, PEP is recommended when a bite, scratch, or mucous membrane exposure occurs, OR when a bat is found in a room with a sleeping person, unattended child, or cognitively impaired individual who cannot reliably report exposure.

2. **Components of rabies PEP** (for previously unvaccinated individuals):
   - **Immediate wound care**: Thorough washing with soap and water for at least 15 minutes
   - **Human rabies immune globulin (HRIG)**: 20 IU/kg, infiltrated around the wound site
   - **Rabies vaccine**: Four doses on days 0, 3, 7, and 14

3. **Rationale for PEP components**:
   - **Wound care**: Physically removes and dilutes viral inoculum; soap has virucidal activity against the lipid envelope
   - **HRIG**: Provides **passive immunity** by immediately neutralizing virus at the wound site before it can enter peripheral nerves; must be given at the wound site to be effective
   - **Rabies vaccine**: Stimulates **active immunity** with antibody production; the vaccine is highly immunogenic and provides long-lasting protection
   - Together, HRIG provides immediate protection while the vaccine generates durable immunity

4. **Prognosis if rabies develops**: Once clinical symptoms of rabies appear, the disease is **virtually 100% fatal**. There are only a handful of documented survivors (typically with severe neurologic sequelae), despite aggressive intensive care. This is why **PEP is so critical** - it is highly effective if given before symptoms develop but useless after. The incubation period (typically 1-3 months, but can be weeks to years) provides a window for PEP to work.

---

## Case 3: HIV Acute Retroviral Syndrome

### Presentation
A 24-year-old man presents with 10 days of fever, sore throat, diffuse lymphadenopathy, and a widespread maculopapular rash. He also reports fatigue, myalgias, and headache. He had unprotected sexual intercourse with a new male partner approximately 3 weeks ago. Examination reveals temperature 38.6°C, posterior cervical, axillary, and inguinal lymphadenopathy, pharyngeal erythema without exudates, and a faint maculopapular rash on the trunk. Monospot test is negative. HIV-1/2 antigen/antibody (4th generation) test is positive, but HIV-1 antibody differentiation assay is negative.

### Clinical Image
![Acute HIV rash](image_03.png)
*Maculopapular rash on the trunk during acute HIV infection (acute retroviral syndrome), often accompanying the mononucleosis-like illness.*

**Image Source**: Lecture image - HIV clinical presentations

### Questions

1. **What is the diagnosis, and what do the laboratory findings indicate?**

2. **Why might acute HIV infection be missed if only antibody testing is performed?**

3. **What is the significance of early diagnosis and treatment?**

4. **What public health considerations apply to this case?**

### Answers

1. **Diagnosis and laboratory interpretation**: This is **acute HIV infection** (acute retroviral syndrome), occurring 2-4 weeks after exposure. The laboratory pattern - positive 4th generation antigen/antibody test but negative antibody differentiation assay - indicates **acute infection before antibody seroconversion**. The 4th generation test detects both p24 antigen (present early) and HIV antibodies; positivity with negative confirmatory antibody testing suggests very early infection where only p24 antigen is detectable. An **HIV RNA viral load** should be ordered to confirm; it will be very high during acute infection.

2. **Why antibody-only testing misses acute infection**: During the **"window period"** of acute HIV infection (first 2-4 weeks), the immune system has not yet produced detectable antibodies. Older 3rd generation antibody-only tests can miss acute infection, which is a critical gap because:
   - Viral load is **extremely high** during acute infection
   - Patients are **highly infectious** during this period
   - This period may account for a disproportionate share of transmission events

   The 4th generation antigen/antibody tests reduce this window by detecting p24 antigen, which appears before antibodies. Nucleic acid testing (HIV RNA) can detect infection even earlier.

3. **Significance of early diagnosis and treatment**:
   - **Reducing transmission**: Extremely high viral loads during acute infection make individuals very infectious; early treatment dramatically reduces viral load and transmission risk
   - **Immune preservation**: Early ART initiation preserves CD4 counts and immune function
   - **Reducing viral reservoir**: Some evidence suggests early treatment may limit the size of the latent viral reservoir
   - **Preventing progression**: Untreated acute infection progresses to chronic HIV
   - Current guidelines recommend **immediate ART initiation**, ideally the same day as diagnosis

4. **Public health considerations**:
   - **Partner notification**: The recent sexual partner and any other partners should be notified and tested
   - **Pre-exposure prophylaxis (PrEP)** discussion for ongoing high-risk behavior
   - **Risk reduction counseling**: Consistent condom use, limiting partners
   - **Treatment as prevention (TasP)**: Maintaining undetectable viral load eliminates transmission risk (U=U: Undetectable = Untransmittable)
   - **Reporting**: HIV is a reportable condition; local health departments track cases and assist with partner services